Continuous Glucose Monitoring in Patients With Diabetes Mellitus Type 2 in Secondary Care
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Glycemic variability
研究概览
简要总结
Introduction and objective: The current state of glucose monitoring includes the use of A1C, self-monitoring of blood glucose (SMBG), and continuous glucose monitoring (CGM). CGM technology has got the potential to revolutionize diabetes care in the near future striving to optimal diabetes management and tight glucose control. Until very recently, this determination could only be achieved by the attainment of multiple capillary blood glucose determinations each day and/or measuring hemoglobin A1C. Those methods are not accurate in cases of unrecognized hypoglycemia, unrecognized nighttime events or in cases of large swings in blood glucose. Our aim is to analyze the benefit of tracking patterns of glucose values by using professional CGM technology used for "blinded" collection of glucose data retrospectively in patients with T2DM in secondary care- diabetologist clinic.
详细描述
STUDY DESIGN: An observational, multicenter, cross-sectional study. A total of 20 diabetologist from four Croatian regions will recruit up to ten subjects of both sexes from May 2018 till the end of May 2019, diagnosed with type 2 diabetes mellitus at least one year prior to study entry, aged ≥40 years, with only basal insulin in therapy and with clinical suspicion of hypoglycemia or with disproportion in actual glycaemia and hemoglobin A1c findings. Sociodemographic, laboratory (HbA1c, fasting and postprandial glucose, total cholesterol, and high density cholesterol, and low density cholesterol, triglyceride and serum creatinine) and habits data will be collected.
SETTING: Totally 100 of patients will be included. At diabetologist office each patient wear the device (iPro™2 Medtronic) subcutaneously for up to 7-days and return it to the office for download. Patients only see the CGM data after it's been analyzed by the healthcare professional. A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist who are not familiar to the method will have a short education. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 3 Days 至 8 Days(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •T2DM diagnosed at least one year prior to study entry
- •Only basal insulin in therapy
- •Patients' ability to understand and answer the questionnaire by themselves
- •Signed informed consent
排除标准
- •Known coagulopathy
- •Oral anticoagulants in therapy
- •Skin disease that enables continuous glucose monitor device application
- •Febrile illness
- •Patient's inability to physically visit a general practitioners office
- •Patient's inability to answer the questionnaire by themselves
结局指标
主要结局
Glycemic variability
时间窗: 7 days
Glycemic variability measured by continuous glucose monitor devicein individuals with type 2 diabetes mellitus in secondary care
次要结局
- Hypogliaemia(7 days)
研究者
Maja Baretić
Principal investigator Maja Baretić MD PhD
Croatian Society for Endocrinology and Diabology
